Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.

Wadowski PP, Eichelberger B, Kopp CW, Pultar J, Seidinger D, Koppensteiner R, Lang IM, Panzer S, Gremmel T.

J Cardiovasc Transl Res. 2017 Aug;10(4):359-367. doi: 10.1007/s12265-017-9746-0. Epub 2017 Apr 19.

2.

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.

Amin AM, Sheau Chin L, Azri Mohamed Noor D, Sk Abdul Kader MA, Kah Hay Y, Ibrahim B.

Cardiol Res Pract. 2017;2017:8062796. doi: 10.1155/2017/8062796. Epub 2017 Mar 21. Review.

3.

Hypersensitivity to ticagrelor and low response to clopidogrel: a case report.

Dai J, Lyu S, Ge C.

Asia Pac Allergy. 2017 Jan;7(1):51-53. doi: 10.5415/apallergy.2017.7.1.51. Epub 2017 Jan 26.

4.

Aspirin and clopidogrel resistance using the cone and plate(let) analyser in Indian patients with coronary artery disease.

Koshy SK, Salahuddin S, Karunakaran B, Nalakath SY, Bhaskaran J, Haridas PV, Mandalay A, Faizal A.

Heart Asia. 2014 Nov 7;6(1):159-62. doi: 10.1136/heartasia-2014-010568. eCollection 2014.

5.

Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study.

Muller C, Messas N, Perrin P, Olagne J, Gautier-Vargas G, Cognard N, Caillard S, Moulin B, Morel O.

BMC Nephrol. 2016 Jun 9;17(1):58. doi: 10.1186/s12882-016-0270-2.

6.
7.

Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Winter MP, Koziński M, Kubica J, Aradi D, Siller-Matula JM.

Postepy Kardiol Interwencyjnej. 2015;11(4):259-80. doi: 10.5114/pwki.2015.55596. Epub 2015 Jan 12. Review.

8.

Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.

Kim YS, Lee SR.

Tex Heart Inst J. 2015 Oct 1;42(5):483-6. doi: 10.14503/THIJ-14-4491. eCollection 2015 Oct.

9.

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.

Geisler T, Booth J, Tavlaki E, Karathanos A, Müller K, Droppa M, Gawaz M, Yanez-Lopez M, Davidson SJ, Stables RH, Banya W, Zaman A, Flather M, Dalby M.

PLoS One. 2015 Aug 28;10(8):e0135037. doi: 10.1371/journal.pone.0135037. eCollection 2015.

10.

Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.

Gremmel T, Koppensteiner R, Panzer S.

PLoS One. 2015 Jun 9;10(6):e0129666. doi: 10.1371/journal.pone.0129666. eCollection 2015.

11.

Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).

Droppa M, Tschernow D, Müller KA, Tavlaki E, Karathanos A, Stimpfle F, Schaeffeler E, Schwab M, Tolios A, Siller-Matula JM, Gawaz M, Geisler T.

PLoS One. 2015 Mar 23;10(3):e0121620. doi: 10.1371/journal.pone.0121620. eCollection 2015.

12.

Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.

Zhu HC, Li Y, Guan SY, Li J, Wang XZ, Jing QM, Wang ZL, Han YL.

J Geriatr Cardiol. 2015 Jan;12(1):23-9. doi: 10.11909/j.issn.1671-5411.2015.01.003.

13.

The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis.

D'Ascenzo F, Barbero U, Bisi M, Moretti C, Omedè P, Cerrato E, Quadri G, Conrotto F, Zoccai GB, DiNicolantonio JJ, Gasparini M, Bangalore S, Gaita F.

Biomed Res Int. 2014;2014:610296. doi: 10.1155/2014/610296. Epub 2014 Oct 13. Review.

14.

Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.

Cresci S, Depta JP, Lenzini PA, Li AY, Lanfear DE, Province MA, Spertus JA, Bach RG.

Circ Cardiovasc Genet. 2014 Jun;7(3):277-86. doi: 10.1161/CIRCGENETICS.113.000303. Epub 2014 Apr 24.

15.

The relationship between fractional flow reserve, platelet reactivity and platelet leukocyte complexes in stable coronary artery disease.

Sels JW, Rutten B, van Holten TC, Hillaert MA, Waltenberger J, Pijls NH, Pasterkamp G, de Groot PG, Roest M.

PLoS One. 2013 Dec 31;8(12):e83198. doi: 10.1371/journal.pone.0083198. eCollection 2013.

16.

Evaluation of Aspirin and Clopidogrel resistance in patients with Acute Coronary Syndrome by using Adenosine Diposphate Test and Aspirin Test.

O I, M O, A AS, Hh CH, W SF, Rahman M.

Pak J Med Sci. 2013 Jan;29(1):97-102. doi: 10.12669/pjms.291.2820.

17.

Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention.

Haji Aghajani M, Kobarfard F, Safi O, Sheibani K, Sistanizad M.

Iran J Pharm Res. 2013 Winter;12(Suppl):169-74.

18.

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.

Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K; Working Group on Thrombosis of the European Society of Cardiology.

Eur Heart J. 2014 Jan;35(4):209-15. doi: 10.1093/eurheartj/eht375. Epub 2013 Sep 25. No abstract available.

19.

Genetics of platelet inhibitor treatment.

Trenk D, Hochholzer W.

Br J Clin Pharmacol. 2014 Apr;77(4):642-53. doi: 10.1111/bcp.12230. Review.

20.

State of the art in platelet function testing.

E Kehrel B, F Brodde M.

Transfus Med Hemother. 2013 Apr;40(2):73-86. doi: 10.1159/000350469. Epub 2013 Mar 18.

Supplemental Content

Support Center